Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

  • US 11,071,726 B2
  • Filed: 11/01/2017
  • Issued: 07/27/2021
  • Est. Priority Date: 11/02/2016
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating gastric cancer in a human patient who has not previously received an antineoplastic agent to treat the gastric cancer, the method comprising administering an antineoplastic therapy to the patient once every two weeks, the antineoplastic therapy consisting of:

  • a) 50 or 55 mg/m2±

    5% of liposomal irinotecan,b) 60, 70, or 85 mg/m2±

    5% oxaliplatin,c) 200 mg/m2 of the (l)-form of leucovorin or 400 mg/m2 of the (l+d) racemic form of leucovorin, andd) 2,400 mg/m2 5-fluorouracil;

    to treat the gastric cancer in the human patient.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×